The BET inhibitor JQ1 targets fat metabolism and counteracts obesity
Introduction: Obesity, one of the most frequent health problems in the adult population, is a condition characterized by excessive white adipose tissue accumulation and accompanied by the increased risk to develop other disorders such as type II diabetes, cardiovascular disorders, physical disabilit...
Saved in:
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2025-02-01
|
| Series: | Journal of Advanced Research |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2090123224000511 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832595741897392128 |
|---|---|
| author | Claudia Fornelli Alessia Sofia Cento Lorenzo Nevi Raffaella Mastrocola Gustavo Ferreira Alves Giuseppina Caretti Massimo Collino Fabio Penna |
| author_facet | Claudia Fornelli Alessia Sofia Cento Lorenzo Nevi Raffaella Mastrocola Gustavo Ferreira Alves Giuseppina Caretti Massimo Collino Fabio Penna |
| author_sort | Claudia Fornelli |
| collection | DOAJ |
| description | Introduction: Obesity, one of the most frequent health problems in the adult population, is a condition characterized by excessive white adipose tissue accumulation and accompanied by the increased risk to develop other disorders such as type II diabetes, cardiovascular disorders, physical disability, frailty and sarcopenia. Total fat mass frequently increases during aging, often coexisting with sarcopenia, thus resulting in an emerging condition defined sarcopenic obesity (SO). Our previous data demonstrated the relevant role of the bromo and extra-terminal domain (BET) proteins inhibitor JQ1 in attenuating inflammation and fibrosis in sarcopenic mice. Moreover, we preliminarily observed that JQ1 administration markedly reduces white adipose tissue mass, suggesting a potential role of BET proteins on visceral fat deposition during aging. Objectives: Starting from those observations, the aim of this study was to investigate the ability of JQ1 to reduce adiposity in a chronic diet-induced obesity (DIO) mouse model mimicking the human metabolic syndrome. Methods: Male C57BL/6J mice were divided in subgroups, either fed a standard diet or a high fat diet for 22 or 12 weeks, treated over the last 14 days with JQ1 or with vehicle. Results: The results showed that JQ1 administration reduces fat mass, preserving skeletal muscle mass and function. A direct JQ1 lipolytic effect was demonstrated on mature adipocyte cultures. JQ1-mediated loss of adipose tissue mass was not associated with systemic inflammation or with lipid accumulation in muscle and liver. JQ1 administration did not impinge on skeletal muscle metabolism and oxidative capability, as shown by the lack of significant impact on mitochondrial mass and biogenesis. Conclusion: In conclusion, the current data highlight a potential benefit of JQ1 administration to counteract obesity, suggesting epigenetic modulation as a prospective target in the treatment of obesity and sarcopenic obesity, despite the underlying multiorgan molecular mechanism is still not completely elucidated. |
| format | Article |
| id | doaj-art-29be9d38e5884b999a893b897ba1956e |
| institution | Kabale University |
| issn | 2090-1232 |
| language | English |
| publishDate | 2025-02-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Journal of Advanced Research |
| spelling | doaj-art-29be9d38e5884b999a893b897ba1956e2025-01-18T05:04:16ZengElsevierJournal of Advanced Research2090-12322025-02-0168403413The BET inhibitor JQ1 targets fat metabolism and counteracts obesityClaudia Fornelli0Alessia Sofia Cento1Lorenzo Nevi2Raffaella Mastrocola3Gustavo Ferreira Alves4Giuseppina Caretti5Massimo Collino6Fabio Penna7Department of Clinical and Biological Sciences, University of Torino, Turin, ItalyDepartment of Clinical and Biological Sciences, University of Torino, Turin, ItalyDepartment of Biosciences, University of Milano, Milan, ItalyDepartment of Clinical and Biological Sciences, University of Torino, Turin, ItalyDepartment of Neurosciences “Rita Levi Montalcini”, University of Torino, Turin, ItalyDepartment of Biosciences, University of Milano, Milan, ItalyDepartment of Neurosciences “Rita Levi Montalcini”, University of Torino, Turin, ItalyDepartment of Clinical and Biological Sciences, University of Torino, Turin, Italy; Corresponding author at: Department of Clinic al and Biological Sciences, University of Torino, Turin, Italy. Tel.: +39 011 670 7759.Introduction: Obesity, one of the most frequent health problems in the adult population, is a condition characterized by excessive white adipose tissue accumulation and accompanied by the increased risk to develop other disorders such as type II diabetes, cardiovascular disorders, physical disability, frailty and sarcopenia. Total fat mass frequently increases during aging, often coexisting with sarcopenia, thus resulting in an emerging condition defined sarcopenic obesity (SO). Our previous data demonstrated the relevant role of the bromo and extra-terminal domain (BET) proteins inhibitor JQ1 in attenuating inflammation and fibrosis in sarcopenic mice. Moreover, we preliminarily observed that JQ1 administration markedly reduces white adipose tissue mass, suggesting a potential role of BET proteins on visceral fat deposition during aging. Objectives: Starting from those observations, the aim of this study was to investigate the ability of JQ1 to reduce adiposity in a chronic diet-induced obesity (DIO) mouse model mimicking the human metabolic syndrome. Methods: Male C57BL/6J mice were divided in subgroups, either fed a standard diet or a high fat diet for 22 or 12 weeks, treated over the last 14 days with JQ1 or with vehicle. Results: The results showed that JQ1 administration reduces fat mass, preserving skeletal muscle mass and function. A direct JQ1 lipolytic effect was demonstrated on mature adipocyte cultures. JQ1-mediated loss of adipose tissue mass was not associated with systemic inflammation or with lipid accumulation in muscle and liver. JQ1 administration did not impinge on skeletal muscle metabolism and oxidative capability, as shown by the lack of significant impact on mitochondrial mass and biogenesis. Conclusion: In conclusion, the current data highlight a potential benefit of JQ1 administration to counteract obesity, suggesting epigenetic modulation as a prospective target in the treatment of obesity and sarcopenic obesity, despite the underlying multiorgan molecular mechanism is still not completely elucidated.http://www.sciencedirect.com/science/article/pii/S2090123224000511ObesitySarcopenic obesityJQ1Adipose tissueLipid metabolismLipolysis |
| spellingShingle | Claudia Fornelli Alessia Sofia Cento Lorenzo Nevi Raffaella Mastrocola Gustavo Ferreira Alves Giuseppina Caretti Massimo Collino Fabio Penna The BET inhibitor JQ1 targets fat metabolism and counteracts obesity Journal of Advanced Research Obesity Sarcopenic obesity JQ1 Adipose tissue Lipid metabolism Lipolysis |
| title | The BET inhibitor JQ1 targets fat metabolism and counteracts obesity |
| title_full | The BET inhibitor JQ1 targets fat metabolism and counteracts obesity |
| title_fullStr | The BET inhibitor JQ1 targets fat metabolism and counteracts obesity |
| title_full_unstemmed | The BET inhibitor JQ1 targets fat metabolism and counteracts obesity |
| title_short | The BET inhibitor JQ1 targets fat metabolism and counteracts obesity |
| title_sort | bet inhibitor jq1 targets fat metabolism and counteracts obesity |
| topic | Obesity Sarcopenic obesity JQ1 Adipose tissue Lipid metabolism Lipolysis |
| url | http://www.sciencedirect.com/science/article/pii/S2090123224000511 |
| work_keys_str_mv | AT claudiafornelli thebetinhibitorjq1targetsfatmetabolismandcounteractsobesity AT alessiasofiacento thebetinhibitorjq1targetsfatmetabolismandcounteractsobesity AT lorenzonevi thebetinhibitorjq1targetsfatmetabolismandcounteractsobesity AT raffaellamastrocola thebetinhibitorjq1targetsfatmetabolismandcounteractsobesity AT gustavoferreiraalves thebetinhibitorjq1targetsfatmetabolismandcounteractsobesity AT giuseppinacaretti thebetinhibitorjq1targetsfatmetabolismandcounteractsobesity AT massimocollino thebetinhibitorjq1targetsfatmetabolismandcounteractsobesity AT fabiopenna thebetinhibitorjq1targetsfatmetabolismandcounteractsobesity AT claudiafornelli betinhibitorjq1targetsfatmetabolismandcounteractsobesity AT alessiasofiacento betinhibitorjq1targetsfatmetabolismandcounteractsobesity AT lorenzonevi betinhibitorjq1targetsfatmetabolismandcounteractsobesity AT raffaellamastrocola betinhibitorjq1targetsfatmetabolismandcounteractsobesity AT gustavoferreiraalves betinhibitorjq1targetsfatmetabolismandcounteractsobesity AT giuseppinacaretti betinhibitorjq1targetsfatmetabolismandcounteractsobesity AT massimocollino betinhibitorjq1targetsfatmetabolismandcounteractsobesity AT fabiopenna betinhibitorjq1targetsfatmetabolismandcounteractsobesity |